Bavarian Nordic A/S has revised its fiscal year 2024 guidance, driven by substantial Mpox vaccine orders and enhanced performance in the Travel Health sector. The company now projects annual revenue between DKK 5,400 million and DKK 5,800 million, with an EBITDA ranging from DKK 1,450 million to DKK 1,700 million.
As of now, Bavarian Nordic's stock stands at $11.77, reflecting a 1.25 percent decline on the OTC Markets.
